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Background: Colistin is a 50-year-old antibiotic, the use of which was ceased in the 70s 
and recently resumed as a “salvage therapy” against multidrug-resistant gram-negative 
bacteria, such as Pseudomonas aeruginosa and Acinetobacter baumannii. The narrow 
therapeutic range of colistin makes the choice of its correct dosage crucial, and monitoring 
of blood concentration is occasionally necessary for critically ill patients, including intensive 
care patients subjected to continuous renal replacement therapy. Methods: Two LC–
MS/MS methods were developed and fully validated for the quantitative determination of 
colistins A and B in plasma and dialysis ultrafiltrate (UF) samples, ultimately arising from 4 
patients undergoing continuous venovenous hemodiafiltration (CVVHDF). Results: The 
developed methods proved to be both specific and selective. They showed good fit and 
linearity over the entire range of interest. Trueness and accuracy proved satisfactory. Both 
methods have excellent intraassay precision (percent coefficient of variations were lower 
than 10%) and limit of detection values in the range 20–100 ng/mL, about 1–2 orders of 
magnitude below the concentrations commonly detected in real samples. The mean 
sieving coefficient (SC) values, measured after 10 minutes of CVVHDF, were 0.42 for 
colistin A and 0.48 for colistin B. SC values proved to be quite stable for 24 hours, but then 
declined to 0.24 for colistin A and 0.32 for colistin B, respectively, after 48 hours. At the 
median blood flow and effluent flow rate of 120 and 28 mL/min, clearance values for 
colistin B were higher than 15 mL/min. During the entire duration of CVVHDF sessions, the 
SC and clearance values for colistin A were significantly lower than colistin B. 
Conclusions: Two simple methods for the simultaneous determination of colistins A and 
B have been developed and validated. Their application in the clinical setting 
demonstrates that CVVHDF treatment lasting 48 hours produces a relatively constant and 
efficient removal of the drug.  
 
 






Polymyxins include 5 groups of polypeptidic antibiotics discovered in the 1950s,1 among 
which only polymyxin B and polymyxin E are employed in clinical therapy. Polymyxin E, 
also called colistin, is produced by Bacillus colistinus. This polypeptide mixture is 
constituted by D and L amino acids, such as D-leucine, L-threonine, and L-a-g-
diaminobutyric acid. They are arranged to form cyclic heptapeptides, with a tripeptidic 
lateral chain linked to a fatty acid by covalent a-amidic bond. Colistin included more than 
30 components, distinguished by amino acid and fatty acid residue composition. The 2 
major components are colistin A (polymyxin E1) and colistin B (polymyxin E2). The 
abundance ratio between these 2 colistins in both commercial materials and analytical 
standards is variable and depends on the suppliers and batches.2 
Colistin is used for the treatment of infections caused by gram-negative bacteria. It 
presents hydrophobic and basic properties, respectively, because of the fatty acid residue 
and 5 free amino groups. Colistin interacts with the anionic groups of the 
lipopolysaccharides (LPS) contained in the membrane of gram-negative bacteria, 
displacing Mg2+ and Ca2+ cations from the negatively charged phosphate groups of the 
LPS lipid A. This causes an increased permeability of the membrane, resulting in the 
cellular death.3  
Colistin methanesulphonate (CMS) is a prodrug of colistin, obtained by the reaction of the 
free amino residues of colistin with formaldehyde and sodium bisulfite. It is significantly 
less toxic than colistin. Both CMS and colistin sulphate are scarcely adsorbed by the 
gastrointestinal tract, with the exception of the cases of newborns and patients with gastric 
mucosa alteration. Therefore, colistin is principally administered as CMS by intramuscular 
or intravenous injection. CMS is then hydrolyzed to colistin and other intermediate 
species.4,5 
The use of colistin as an antibiotic agent was ceased in the 70s because of its 
nephrotoxicity and neurotoxicity and was substituted by aminoglycosides. In particular, 
nephrotoxicity was described as the main risk associated with the prolonged administration 
of colistin.6,7 However, recent studies concluded that the nephrotoxicity of colistin is less 
severe than it was reported in the past. In particular, the risk of CMS nephrotoxicity was 
found to be significant only after 14 days of administration.8 Because the risk seems to be 
linked to its cumulative dosage, not to single administration, it stems the need to monitor 
the renal function of patients subjected to prolonged colistin therapy. These differences 
between old and recent toxicological data are because of the improvement of medical 
care, renal function monitoring, and careful selection of coadministered drugs. In the late 
90s, the use of colistin was resumed as a “salvage” therapy against multidrug-resistant 
gram-negative bacteria, such as Pseudomonas aeruginosa, Acinetobacter baumannii, and 
Klebsiella pneumoniae,9 because new resistant bacteria strands could not be eradicated 
by traditional or last-generation antibiotics. 
The pharmacokinetic and pharmacodynamic data about CMS and colistin are relatively 
scarce, since 1959, when they entered in clinical use, the strict drug development 
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procedures that are now mandatory were not required yet. It follows that dosage regimens 
are rarely described for specific categories of patients, in particular for critically ill patients 
with altered renal function and subjected to renal replacement therapies.3 
Recommended CMS dosage during hemodialysis is 80 mg after each cycle of dialysis,10 
but the clearance conditions observed in this case are different from those of patients 
subjected to continuous renal replacement therapy (CRRT) when clear pharmacological 
indication is missing.11 A few studies showed that the pharmacokinetics of CMS/colistin is 
altered in patients under critical conditions5 or affected by cystic fibrosis.12 The colistin 
clearance is essentially not renal, and no correlation was found between colistin and 
creatinine clearance.13 However, creatinine clearance significantly affects the total body 
clearance of CMS and colistin.14 
The first pharmacokinetics of colistin was obtained by microbiological experiments.15 
Afterwards, analytical methods based on immunological assays, thin layer 
chromatography, capillary electrophoresis, and high-pressure liquid chromatography 
(HPLC) were developed. More recently, LC–MS/MS methods have been developed for the 
determination of polymyxin B1 and B2,16 colistin, and CMS in plasma and other biological 
samples,17,18 including UF.19 No reference methods exist for separate quantitative 
determination of colistins A and B, but rather a few laboratories developed and validated 
in-house methods, addressed to the measurement of polymyxin and colistin in human 
plasma.16,18 After considering the existing methods, we developed and validated 2 LC–
MS/MS methods devoted to the quantitative determination of colistins A and B in plasma 
and UF, respectively, using polymyxin B as the internal standard (IS). In addition, our 
analytical protocols were applied to monitor colistin concentrations in plasma and UF 
arising from critically ill patients undergoing CRRT. This allowed us to study colistin 
extracorporeal clearance and its removal efficiency over the dialysis session. 
 




Colistin sulphate, polymyxin B sulphate, acetonitrile, formic acid, and methanol were 
purchased from Sigma Aldrich (Milan, Italy). Acetone was from Carlo Erba (Milan, Italy). 
Sep-Pac Vac 3 cc (200 mg) C18 solid phase extraction cartridges were obtained from 
Waters (Milan, Italy). Highly purified water was produced by Millipore Milli-Q UF Plus 
system (Millipore, Bedford, MA).  
 
Plasma and UF Samples 
 
Human blank plasma was obtained from healthy volunteers. The solution for 
hemodiafiltration CB 32-HDF B200 was purchased from NovaSelect S.p.A (Potenza, Italy). 
Ex vivo samples were obtained from critically ill patients undergoing CRRT at the Intensive 
Care Department, CTO Hospital (Ospedale CTO), Turin (see Patients). To avoid 
degradation of CMS during sampling, blood samples were directly chilled and thereafter 
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centrifuged as soon as possible. Plasma samples were then stored at 280°C until 
analysis.20  
 
Stock and Working Standard Solutions 
 
Stock standard solutions of colistin and polymyxin B (IS) were prepared in water with 0.1% 
formic acid, at a concentration of 1000 mcg/mL. Working standard solutions were obtained 
by appropriate dilutions. Stock and working standard solutions were stored at 2208C in the 
dark.  
 
Sample Preparation for Colistin 
Determination in Plasma 
 
The samples were quickly thawed in cold water in batches of 12 samples or less. Hundred 
microliters of human plasma was transferred into a 10-mL glass tube. Twenty microliters of 
the IS working solution (10 ng/mL) and 200 mL of acetone were added in sequence. The 
sealed tube was shaken vigorously for 3 minutes by means of a vortex multimixer 
(Tecnovetro, Monza, Italy) and then centrifuged at g value of 1459 m/s2 for 5 minutes 
(model Megafuge 1.0 Heraeus; ASHI, Milan, Italy). Two hundred microliters of the 
supernatant was transferred into a new 10-mL glass tube and evaporated to dryness 
under a gentle stream of nitrogen and mild heating (408C), using a Techne Sample 
Concentrator (Barloworld Scientific, Stone, UK). The residue was redissolved in 100 mL of 
0.1% HCOOH/CH3CN (95:5, vol/vol) solution and transferred into the analytical vial for the 
HPLC–MS/MS analysis. Because worked-up samples were verified to be stable at low pH 
values for 5 hours at least,20 their instrumental analysis was always planned within 2 
hours from the end of the preparation step. 
 
Sample Preparation for Colistin 
Determination in UF 
 
The samples were quickly thawed in cold water in batches 12 samples or less. A 50 mL 
aliquot of UF real sample was transferred into a 10-mL glass tube and diluted with 50 mL 
of solution for hemodiafiltration. Twenty microliters of the IS working solution (10 ng/mL) 
and 50 mL of drug-free human plasma were added to the same glass tube. Then, the 
sample volume was brought to 1 mL by adding highly purified water and was briefly vortex-
mixed. The mixture was loaded onto a solid phase extraction column, preconditioned with 
1 mL of methanol followed by 1 mL of water. The column was subsequently washed with 1 
mL of water, and the analytes were eluted with 1 mL of 0.1% (vol/vol) formic acid in 
methanol. Then, the eluate was evaporated to dryness under a gentle stream of nitrogen 
at 408C, and the residue was redissolved in 100 mL of 0.1% HCOOH/CH3CN (95:5, 
vol/vol) solution and transferred into the analytical vials for the LC–MS/MS analysis. As for 
plasma samples, the instrumental analysis was always executed within 2 hours after the 





The chromatographic separation was performed by an Agilent 1100 series liquid 
chromatograph (Agilent Technologies, Palo Alto, CA), including a vacuum degasser, a 
binary pump, an autosampler, and a column thermostat. The liquid chromatograph was 
equipped with a Phenomenex Synergi Fusion-RP C18 80 Å (4 mm) 150 · 2.00 mm column 
and a Phenomenex SecurityGuard 4.0 · 2.0 mm precolumn. The chromatographic run was 
carried out using a binary mobile phase of 0.1% HCOOH in highly purified water (A) and 
0.1% HCOOH in acetonitrile (B), under the following program: linear gradient from 95% to 
50% acetonitrile in 2 minutes, linear gradient from 50% to 95% acetonitrile in 1 minute, 
isocratic with 95% acetonitrile for 8 minutes, total run time: 11 minutes. The injection 
volume was 20 mL, and the flow rate was 0.3 mL/min. The LC was interfaced to an 
Applied Biosystems API 3200 triple quadrupole mass spectrometer (Applied Biosystems 
Sciex, Ontario, Canada), operating in the electrospray ionization (ESI)—positive ion mode. 
The other MS parameters were set as follows: curtain gas, 25 psi; collision gas, 10 psi; ion 
spray voltage, 2500 V; probe temperature, 5008C; ion source gas-1, 50 psi; ion source 
gas-2, 40 psi; entrance potential, 10 V; collision cell exit potential, 10 V. Ion acquisition 
was operated at unit mass resolution in the selected reaction monitoring (SRM) mode, 
using the doubly charged molecular ion [MH2]2+ as the precursor ion, both for colistin and 
IS. The doubly charged ions are more intense than the singly charged ions, as already 
reported by Sin et al (Sin et al, 2005). The SRM ion transitions considered, together with 
the relative values for declustering potential and collision energy, are reported 




All the validation parameters generally required for quantitative bioanalytical procedures21 
were determined, including selectivity, linearity, stability, inaccuracy, imprecision, lower 
limit of quantification (LLOQ), limit of detection (LOD), and recovery. Moreover, validation 
parameters typical for LC–ESI-MS methods were assessed, including matrix effects (ME) 




Ten samples of blank plasma and 10 aliquots of blank UF were analyzed. The occurrence 
of possible interferences from endogenous substances was tested by monitoring the SRM 




The selectivity was evaluated at 2 concentrations. Twenty samples of negative plasma and 
20 aliquots of UF were spiked with colistins A and B and then analyzed. The 2 spiking 
levels for colistins A and B in plasma samples were respectively 305 and 618 ng/mL (low 
level) and respectively 3050 and 6180 ng/mL (high level). The 2 spiking concentrations for 
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colistins A and B in UF samples were 152.5 and 309 ng/mL (low level) and 1525 and 3090 




Calibration curves for colistins A and B in plasma and UF matrices were built by spiking 
blank real samples with the appropriate concentrations of the analytes. Each curve 
included 6 concentration levels (including zero level), over a range covering the 
concentrations expected in the real samples obtained from patients. The investigated 
ranges were 0–9150 ng/mL for colistin A (0, 152.5, 305.0, 1525, 3050, and 9150 ng/mL) 
and 0–18,540 ng/mL for colistin B (0, 309, 618, 3090, 6180, and 18,540 ng/mL) in plasma 
matrix and 0–3050 ng/mL for colistin A (0, 91.5, 152.5, 305.0, 1525, and 3050 ng/mL) and 
0–6180 ng/mL for colistin B (0, 185.4, 309, 618, 3090, and 6180 ng/mL) in UF matrix. 
Each level was determined in triplicate for the plasma matrix and in duplicate for the UF 
matrix. 
 
Inaccuracy and Trueness 
 
The inaccuracy is expressed as the percent deviation from the accepted reference value 
and is used to evaluate the systematic error of the method.21 The inaccuracy was 
calculated by comparing the concentrations determined in the spiked samples used for the 
specificity tests with their nominal concentration. Both within-run and between-run 




The imprecision is generally expressed as an absolute or relative standard deviation from 
the mean of repeated determinations. We evaluated the repeatability of the method, 
representing the imprecision under the same operating conditions, over a short interval of 
time, usually defined as within-run imprecision.21 We evaluated also the repeatability of 
the method over a longer interval of time, usually defined as between-run imprecision. 
Both within-run and between run imprecision were determined at 2 concentration levels, as 
percent coefficient of variation (CV%) from the mean values. 
 
Limit of Detection 
 
LOD is the lowest concentration of the analyte in a real sample, for which specific 
identification criteria can still be fulfilled.21 LODs were calculated from the signal-to-noise 
(S/N) values obtained from the chromatographic profiles of the SRM transition with the 
lowest intensity among the SRM transitions characterizing each analyte. S/N values were 
extrapolated from the 3 lowest levels of the calibration curves. Calculated LOD values 
were experimentally confirmed by analyzing further spiked samples at concentrations 
slightly higher than the calculated LODs. 
 
Lower Limit of Quantification 
 
The LLOQ is the lowest amount of the analyte in a real sample that may be quantitatively 
determined with suitable precision and accuracy.21 LLOD values were calculated as 3 





The stability of standard solutions had been carefully evaluated by Orwa et al.22 Their 
results indicate that colistin and polymyxin B are susceptible to degradation in both neutral 
and basic condition (pH . 5). Accordingly, our stock and working solutions were prepared 
in HCOOH 0.1%,22 and were periodically tested for stability throughout the study. 
 
ME and Recovery 
 
Suppression or enhancement of the ionization of the analytes by the effect of coeluting 
compounds is a well known phenomenon occurring in LC–MS analysis, especially when 
ESI is used. Recovery represents the percentage of the analyte still present after sample 
workup, as compared with the amount of the analyte initially contained in the sample. ME 
and recovery were determined within the same analytical session by preparing 3 sets of 
samples, each including 5 replicates. In the first set, blank plasma and UF samples were 
spiked with the analytes before the extraction step; in the second set, working solutions of 
the analytes were added (at the same concentrations) on the blank plasma and UF 
extracts; the third set was represented by the working solutions at the same 
concentrations. The recovery of the analytes was calculated by the ratio between the 
analyte concentration determined after its extraction (first set) and that determined on the 
spiked extract (second set). The ME was calculated as the percentage ratio between the 
analyte chromatographic peak area detected from the second set and that detected from 
the third set. The difference with respect to 100% highlighted matrix suppression (values 
below 100%) or enhancement (values above 100%).21 ME was determined also for the 
ISs, at the concentration used in analysis of real samples. IS-normalized ME have been 




Carryover effect was evaluated by injecting an alternate sequence of blank plasma (and 
UF) samples and samples spiked with the analytes at the highest concentration of the 
calibration curves (plasma spiked at 9150 ng/mL for colistin A and 18,540 ng/mL for 
colistin B; and UF spiked at 3050 ng/mL for colistin A and 6180 ng/mL for colistin B). 
Carryover effects were positively detected when the S/N values for SRM chromatographic 
profiles exceeded 3, in the analysis of blank samples.  
 
Ex Vivo Study 
Patients 
 
Four serial critically ill patients, admitted to the Intensive Care Department at CTO 
Hospital, with severe sepsis/septic shock sustained by infection of multiresistant gram-
negative bacteria were included in this study (Table 3). All these patients showed residual 
sensibility to colistin, suffered from acute kidney injury, and underwent continuous 
venovenous hemodiafiltration (CVVHDF) with regional citrate anticoagulation. The study 
protocol was in accordance with the Helsinki Declaration. Informed written consent was 








CVVHDF procedures were standardized and carried out with a Multi-filtrate apparatus 
(Fresenius Medical Care AG, Bad Homburg, Germany) equipped with high-flow 
polysulfone filter (AV1000, surface area of 1.8 m2; Fresenius Medical Care) and setting 
replacement fluid infusion in predilution. The blood circuit was treated with citrate (ACD-A 
[Anticoagulant Citrate Dextrose Solution A]-containing replacement solution infused in 
predilution; citrate concentration, 28.8 mmol/L) to prevent coagulation and to reduce the 
risk of hemorrhagic complications.24 Calcium replacement infusion was prepared by using 
a commercial 10% calcium chloride solution infused in a separate line at the end of the 
venous circuit.25 The CVVHDF blood flow rate was set at 120 mL/min and the predilution 
infusion rate at 900 mL/h to reach a prefilter serum citrate of 3.3 mmoL/L. Administration of 
calcium chloride 10% solution started at a flow rate of 4.0 mL/h, followed by 0.5 mL/h 
increments for each effluent increase of 500 mL.26 Dialysate flow rate was started at 800 
mL/h, and was modified according to the patients’ metabolic and fluid balance 
requirements. As dialysate, calciumfree fluid-containing bags (CiCa bag; Fresenius 
Medical Care) were used. 
 
Colistin Methanesulphonate Infusion and Sampling Protocol 
 
Colistin methanesulphonate (Colimicina; UCB Pharma SpA, Pianezza, Italy) was 
administered at the dose of 4.5 · 106 units (equivalent to 360 mg of CMS, or 135 mg of 
colistin base equivalent27) in 250 mL of normal saline solution every 12 hours by 
intravenous infusion for more than 60 minutes. Because of the lack of clear 
recommendations based on clinical evidence, CMS dose typically prescribed was not 
modified for patients undergoing CRRT.5 In 1 patient (patient 4), the administered dose 
was 3.0 · 106 units (equivalent to 240 mg of CMS) every 12 hours intravenously of more 
than 60 minutes. All samples were taken from patients after the third day of therapy with 
colistin that is at the pharmacokinetic steady state condition. Samples were drawn 
respectively at 10 minutes, 3, 24, and 48 hours after the beginning of the dialysis session 
(Table 4). Further samples were collected at 6 and 12 hours, whenever possible. 
Blood samples were drawn directly from systemic arterial blood for measuring plasma 
concentration of colistin entering the filter (Cpl-in) and from the circuit venous line 
(between the filter and the venous air bubble trap) for measuring plasma concentration of 
colistin leaving the filter (Cpl-out). Ultrafiltrate samples were taken from the ultrafiltrate line 
(C-UF). Plasma and effluent samples were stored at 2208C and were analyzed within a 
week. Colistin extraction depends on its sieving coefficient (SC), that is, the concentration 
in ultrafiltrate (C-UF) divided by the mean of concentrations in pre- and post-filter blood 
[(Cpl-in + Cpl-out)/2]. Calculated filter clearance of colistin A (Clear Filter, expressed as 
mL/min), is given by the product of SC and the ultrafiltration rate (eff flow), expressed as 




The software program Statistica (Statistica 6.1; Stat-Soft Inc, Tulsa, OK) was used for 
descriptive statistics and graphs. All values were expressed as median (interquartiles 







Validation of the Analytical Methods 
 
Figure 1 shows typical SRM chromatographic profiles for colistin A, colistin B, and the ISs, 
polymyxin B1, and B2. Although the chromatographic peaks seem to be overlapped, all 
SRM transitions for the 4 compounds are different, resulting in separate acquisition 
channels and yielding no interferences among analytes and IS, as is evident in Figure 1. 
The LC elution program needed an initial pulse of high acetonitrile content to control the 
chromatographic peak width, followed by a regular gradient, as is described in a previous 
study.28 A summary of validation results is reported in Table 2. 
 
Specificity and Selectivity 
 
The virtual absence of any interfering signal (S/N , 3) in the SRM chromatograms at the 
retention times of the analytes of interest was verified for all blank samples, demonstrating 
that the method is specific for the tested compounds and free from positive interference 
from other plasma and UF components. The analytes were clearly identified in all the 
spiked samples, according to the criteria reported in the WADA Technical Document—




The calibration curves obtained for colistins A and B in both plasma and UF showed good 
fit and linearity over the entire range of interest. The resulting R2 values ranged from 
0.9970 to 0.9995.  
 
Inaccuracy and Trueness  
 
For both methods, experimental trueness values proved satisfactory, yielding percent 
deviations lower than 615%. The same conclusion applies to inaccuracy evaluation; only 
for colistin A at the low spiking level in plasma, a few single determinations exhibited 




All experimental CV% were lower than 10% for both the methods (Table 2), proving that 
the methods have excellent within-run and between-run precisions. 
 
LOD and LLOQ 
 
All LOD values reported in Table 2 are in the range 20–100 ng/mL, about 1–2 orders of 
magnitude below the concentrations commonly detected in the real plasma and UF 
samples. Also LLOQ concentration values are significantly lower than those recorded in 
real samples, demonstrating that the methods are suitable to provide unequivocal 








Using the storage conditions described in the previous section, stock and working 
solutions proved to be stable for the entire period of the present study. Fresh working 
solution was periodically prepared. 
 
ME and Recovery 
 
Homogeneous and significant signal suppression because of the matrix was observed for 
colistins A and B, and polymyxins B1 and B2, as expected for structurally similar and 
partially coeluting substances. In plasma samples, ME ranges from 27% to 39% for 
analytes and IS at both low and high validation levels, with slightly lower values (higher 
ME) at high concentration. Similar percentages were observed in UF samples, again with 
slightly higher effects recorded at high concentrations. The ME homogeneity and stability 
between analytes and IS provide similar signal suppression and a compensating outcome, 
resulting in accurate and repeatable quantitative determinations, as described above. The 
ISnormalized ME was calculated at low and high concentration levels and the observed 
CV% proved not to be larger than 15%, as prescribed by EMA (European Medicines 
Agency) Guidelines.23 Recoveries were also uniform for all colistins and polymyxins, 
ranging from 46% to 62% for plasma samples, and from 66% to 84% for UF samples. The 
addition of blank human plasma to the UF in the sample preparation was necessary to 
obtain good extraction efficiency from UF samples. The incomplete recovery of analytes 
and IS from both matrices has to be attributed to a partial coprecipitation of these 





Both methods proved to be affected by carryover effect. This is likely to be caused by 
colistin adsorption on various materials, as reported by Gobin et al4 and by Jansson et 
al.20 To avoid contamination between consecutive samples, 1 injection and subsequent 
chromatographic run of pure solvent (acetonitrile) into the LC–MS/MS instrument was 
executed after each sample. The virtual absence of further carryover effect using this 
procedure was positively verified (Fig. 1).  
 
Ex Vivo Concentrations Measurement and Clearances of Colistin in CVVHDF 
Patients 
 
The experimental protocol envisaged that samples were collected after 10 minutes, 3 
hours, 24 hours, and 48 hours, at least, after the beginning of the CVVHDF session. 
Problems encountered during the intensive care for these critical patients resulted in 
occasional impracticality to collect the samples at the planned time. For 1 patient, 
additional sampling after 6 and 12 hours was done (Table 4). The absolute concentrations 
measured in blood samples depend on several parameters, including dosage, time of 
administration, body-mass index, and others. For our aim, much more interesting is the 
ratio between UF and blood concentration, that is, the SC, which illustrates the colistin 
distribution in the 2 phases. To make this information clearer, the SC values have been 
averaged for 4 patients, whenever possible. The outcome is reported in Figure 2. After 10 
minutes of CVVHDF, SC values were 0.42 for colistin A and 0.48 for colistin B (Fig. 2). 
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Apart from colistin B, whose SC peaked to 0.58 after 3 hours, SC values proved to be 
quite stable for 24 hours, but declined to 0.24 for colistin A and 0.32 for colistin B after 48 
hours (Fig. 2). During the entire duration of the of CVVHD sessions, the SC values for 
colistin A were significantly lower than those for colistin B. Figure 3 shows the clearance 
values for colistins A and B. The highest clearance values (above 15 mL/min) were found 
after 3 and 6 hours for colistin B at the median blood flow and effluent flow rate of 120 and 
28 mL/min, respectively. The global trends depicted in Figure 3 closely resemble the SC 
pattern depicted in Figure 2, showing reduced clearance values after 48 hours and lower 
clearance values measured for colistin A than for colistin B. In particular, clearance values 
declined for all patients during the CVVHDF session, reaching half the starting value after 




Development of the Methods 
 
Colistins A and B are not commercially available as separated pure reference standards, 
but are sold as mixtures. To evaluate the relative abundance of the 2 components, it was 
assumed that colistins A and B had the same response factors for the corresponding SRM 
transitions. This assumption is reasonable, because the 2 molecular structures differ only 
for a single CH2 group. The percentage of each component was determined by the peak 
area for its main SRM transition with respect to the sum of peak areas for the 2 
components.17 Polymyxin B was used as the IS. Like colistin, polymyxin is a mixture of 
various polypeptidic compounds with similar molecular structures, but the main 
components are polymyxin B1 and polymyxin B2. Polymyxin B1 is generally chosen as the 
IS for both colistin A and colistin B. In the course of our validation experiments, we noticed 
that the use of polymyxin B1 as the IS in UF samples produced a moderate overestimation 
of colistin B, whereas it was optimal for the determinations of both colistin homologues in 
plasma and for colistin A in UF samples (see IS-normalized ME in Table 2). Similar 
phenomenon has been reported by Thomas et al16; they developed a LC–MS/MS method 
for polymyxin B1 and polymyxin B2, with colistin as the IS, where they observed significant 
ionization enhancement at low polymyxin concentrations when colistin was present. This 
effect was observed to become less pronounced at higher polymyxin B1 and B2 
concentrations. Their analytical strategy led them not to use any internal 
standardization.16 In our case, more accurate quantification was obtained by averaging 
the signals of polymyxin B1 and polymyxin B2 to yield more closely 
matching results. 
 
Results in Patients Undergoing CVVHDF 
 
Colistin monitoring is occasionally needed in patients undergoing dialysis therapy, in that 
case, the renal clearance is impaired, and a fraction of the drug is eliminated through the 
ultrafiltrate effluent. Renal function, expressed as creatinine clearance, is the main 
pharmacokinetic factor involved in the maintenance dose of colistin methanesulphonate.14 
Out of an estimated colistin total body clearance of 45.3 mL/min (the sum of renal 
clearance and non-renal-dependent component), 29.4 mL/min is the estimated volume 
because of renal clearance. 14 When the renal function is severely impaired and the 
patient undergoes renal replacement therapy, the renal component of total colistin 
clearance is virtually absent and has to be substituted by filter clearance. The 
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extracorporeal clearance of colistin depends on its elimination through the polysulfone 
dialysis membrane, characterized by an anionic surface without adsorptive properties. This 
polysulfone material forms a membrane allowing high flow and is able to remove 
substances with molecular weight up to 30 kDa.30 Because colistin has a molecular 
weight slightly exceeding 1 kDa, it freely crosses this polysulfone membrane, leaving a 
reduced concentration in the blood stream after the dialysis. The whole fraction of colistin 
eliminated by the CVVHDF procedure is supposed to be found in the effluent. The colistin 
SC value depends on the properties of both the membrane and solute and is 
experimentally determined to measure the removal efficiency of the filter. For example, 
progressive filter clogging is evidenced by a decay of the SC. Figure 2 evidences that the 
initial SC for colistin A and B (0.42 and 0.48, respectively) declined to about 0.24 and 0.32 
after 48 hours of continuous use. Even though colistin is mostly bound to albumin in 
plasma, the free colistin fraction in the blood stream has been recently evaluated as 
34%.31 Colistin A is likely to be more extensively bound to albumin than colistin B, 
because of its longer fatty acid residue,31 which explains its  lower SC. In fact, only the 
free plasmatic fractions of colistins A and B can cross the dialysis membrane and reach 
the effluent. Besides this difference, the SC values for colistins A and B are relatively high, 
with a mean SC of 45% at the beginning of treatment (Fig. 2) and the removal efficiency of 
the system is still relatively high at the end of treatment, when the membrane efficiency is 
known to be affected by extensive fouling processes.32 From Figure 3, it is possible to 
evaluate the efficiency of colistin removal during a therapeutic session. In the early hours 
of CRRT at a blood flow of 120 mL/min and effluent rate of 2 L/h, the clearances of 
colistins A and B were at about 11 and 15 mL/min, respectively; then, they slowly declined 
along the treatment. From these data, the total colistin removal from the blood stream can 
be calculated from mean clearance values of 9.4 and 12.8 mL/min for colistins A and B, 
respectively. The measured filter clearance of colistin is about 40% of the renal clearance 
observed for patients with normal renal function (at a creatinine clearance of 120 mL/min). 
In addition, the dialytic colistin removal efficiency could be further improved, whenever 





The 2 LC–MS/MS methods developed and validated for the quantitative determination of 
colistins A and B in human plasma and ultrafiltrate proved to be adequate to measure the 
distribution of colistin administered to critically ill patients with renal failure and subjected to 
CRRT. In particular, these methods were successfully applied to measure the 
concentration of colistins A and B in real samples from 4 patients undergoing CVVHDF. 
The experimental results proved that colistin B crossed the dialytic polysulfone membrane 
more freely than colistin A, resulting in a more extensive elimination through the ultrafiltrate 
flow. The SCs experimentally measured for both colistins from ex vivo patients proved to 
be close to the values expected on the basis on membrane cutoff and a plasma-free 
colistin fraction of 34%. 
The clearances for colistins A and B were sufficiently stable over the entire length of the 
dialysis section to produce a constant and efficient drug removal during 48 hours of the 
CVVHDF treatment. Even if the clearance of colistins A and B, that the polysulfone filter 
can produce, is limited to the exchangeable free colistin fraction, their experimental values 
represent a significant fraction (about 40%) of expected renal clearance in patients with 
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Retention times, SRM transitions, and optimal declustering potential and collision energy for the analytes and 
internal standards in tandem mass spectrometry experiments. 
 
Analyte Retention time (min) SRM ions (m/z)  Declustering Potential (V) Collision Energy (V) 
 
5.66 
585.7/101.1   53 
Colistin A 585.7/241.3 42 29 
 585.7/202.3  31 
 
5.55 
578.7/101.1  50 
Colistin B 578.7/227.3 43 31 
 578.7/202.3  33 
 
5.72 
602.6/101.3  49 
Polymyxin B1 602.6/202.1 40 33 
 602.6/241.2  28 
 
5.61 
595.6/100.9  53 
Polymyxin B2 595.6/184.3 45 48 





Method validation results, including intralaboratory precision, trueness, matrix effect and recovery, at low and high concentration, plus LOD (calculated and evaluated) 
LOQ and R
2 









 Plasma UF 
Colistin A 
305.0 152.5 Within-run precision as CV% (low level) 6.31% 4.27% 
3050 1525 Within-run precision as CV% (high level) 4.28% 3.30% 
305.0 152.5 Between-run precision as CV% (low level) 5.92% 6.21% 
3050 1525 Between-run precision as CV% (high level) 6.36% 8.99% 
305.0 152.5 Within-run trueness (n =10) (low level) 85.4% 101.2% 
3050 1525 Within-run trueness (n = 10) (high level) 99.6% 102.8% 
305.0 152.5 Between-run trueness (n = 5) (low level) 98.2% 109.7% 
3050 1525 Between-run trueness (n = 5) (high level) 95.6% 103.8% 
305.0 152.5 Matrix effect (low level) 27% 31% 
3050 1525 Matrix effect (high level) 27% 22% 
305.0 152.5 Recovery (low level) 62% 68% 
3050 1525 Recovery (high level) 46% 81% 
LOD calculated (ng/mL) 18.5 19.4 
LOD evaluated (ng/mL) 45.7 30.5 
LOQ (ng/mL) 152 91.5 
R2 0.9970 0.9978 
Colistin B 
618.0 309.0 Precision as CV% (low level) 4.27% 5.45% 
6180 3090 Precision as CV% (high level) 3.30% 7.11% 
     
     
618.0 309.0 Trueness (low level) (n =10) 564.524.8 ng/mL 305.516.7 ng/mL 
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6180 3090 Trueness (high level) (n = 10) 6478213 ng/mL 3000213 ng/mL 
     
     
618.0 309.0 Matrix effect (low level) 39% 36% 
6180 3090 Matrix effect (high level) 31% 32% 
618.0 309.0 Recovery (low level) 53% 66% 
6180 3090 Recovery (high level) 51% 66% 
LOD calculated (ng/mL) 34.0 33.9 
LOD evaluated (ng/mL) 92.0 61.8 
LOQ (ng/mL) 306 185 
R2 0.9987 0.9995 
Polymyxin B1 
849 1359 Matrix effect 30% 34% 
849 1359 Recovery 50% 84% 
Polymyxin B2 
225 361 Matrix effect 32% 33% 





















1 58 M Burns 60% 5 0.60/3.0 Acinetobacter Baumanni YES 
2 60 M Ulceration in diabetes 14 0.30/3.0 Acinetobacter Baumanni NO 
3 89 M Burns  40% 3 0.50/9.0 Acinetobacter Baumanni YES 
4 62 M Pneumonia 3 0.00/8.0 Klebsiella Pneumoniae NO 
a







Blood (pre- and post-filter) and ultrafiltrate colistin A and B concentrations in real samples for four serial critically ill 
patients undergoing CVVHDF. 
 
Patient Collection time 
[Colistin A] (g/mL) [Colistin B] (g/mL) 
Pre-filter Post-filter Ultrafiltrate Pre-filter Post-filter Ultrafiltrate 
1 
10 min 3.75 3.07 1.16 1.63 1.56 0.78 
3 h 4.39 3.78 1.34 1.88 1.80 1.10 
24 h 5.25 4.57 2.06 2.24 2.05 1.34 
2 
3 h 5.39 4.26 1.32 2.23 1.80 0.89 
24 h 8.80 8.81 2.16 4.50 3.33 1.39 
48 h 9.47 8.08 2.08 3.29 2.78 0.97 
3 
10 min 5.00 4.21 2.30 1.78 1.10 0.68 
3 h 5.31 4.88 2.00 1.75 1.65 0.75 
24 h 5.04 5.43 2.25 1.42 1.45 0.73 
24 h (+1 day) 6.54 5.49 1.97 2.10 1.68 0.71 
24 h (+5 day) 5.75 4.12 2.24 1.89 1.13 0.60 
24 h (+8 day) 4.96 4.71 1.84 1.73 1.26 0.57 
4 
3 h 1.61 1.54 0.73 0.32 0.29 0.27 
6 h 2.06 2.34 0.83 0.43 0.49 0.26 
12 h 1.90 2.00 0.69 0.44 0.46 0.22 







FIGURE 1. A, SRM chromatographic profiles for blank plasma; B, Blank plasma spiked at LOQ levels for both colistins; 
C, Pre-filter plasma of patient 1 collected 10 minutes after the beginning of the CVVHDF session; D, Blank UF; E, blank 
UF spiked at LOQ levels for both colistins; and F, UF of patient 1 collected 10 minutes after the beginning of the 










FIGURE 3. Extracorporeal clearance of colistins A and B during 48-hour CVVHDF sessions. 
